Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention

Journal of Thrombosis and Thrombolysis

Volumn 34, Issue 4, 2012, Pages 499-505

  Li, Yiding ^a   Tai, Bee Choo ^b   Sia, Winnie ^c   Phua, Qian Hui ^a   Richards, Mark A ^c   Low, Adrian ^c   Chan, Koo Hui ^c   Teo, Swee Guan ^c   Sim, Tiong Beng ^c   Lee, Chi Hang ^c   Roe, Matthew T ^d   Yeo, Tiong Cheng ^c   Tan, Huay Cheem ^c   Chan, Mark Y ^c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Acute myocardial infarction; Percutaneous coronary intervention; Platelet reactivity; Thienopyridine

Indexed keywords

CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PRASUGREL;

ADULT; AGE; ANGIOCARDIOGRAPHY; ARTICLE; ASIAN; BLEEDING; BLOOD CLOT LYSIS; BODY MASS; CARDIOVASCULAR PARAMETERS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DRUG FATALITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PILOT STUDY; PLATELET REACTIVITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE FUNCTION; TREATMENT OUTCOME; VASODILATOR STIMULATED PHOSPHOPROTEIN INDEX;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; CORONARY THROMBOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREOPERATIVE CARE; SINGAPORE; THIOPHENES; TICLOPIDINE;

EID: 84868205680     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0782-y     Document Type: Article

References (16)

1. Sabatine MS, Cannon CP, Gibson CM et al (2005) Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics. The PCI-CLARITY study. J Am Med Assoc 294(10):1224-1232 (Pubitemid 41352110)
2. Hasegawa M, Sugidachi A, Ogawa T et al (2005) Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb Haemost 94:593-598 (Pubitemid 41300857)
3. Montalescot G, Wiviott SD, Braunwald E et al (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373:723-731
4. Patti G, Barczi G, Orlic D et al (2011) Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study. J Am Coll Cardiol 58:1592-1599
5. Small DS, Payne CD, Kothare P et al (2010) Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial. Clin Ther 32:365-379
6. van Werkum JW, van der Stelt CA, Seesing TH et al (2007) The flow cytometric VASP assay can be used to determine the effectiveness of clopidogrel in patients treated with abciximab. J Thromb Haemost 5:881-883 (Pubitemid 46563598)
7. Gibson CM, Cannon CP, Daley WL et al (1996) TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 93:879-888 (Pubitemid 26074824)
8. Bonello L, Tantry US, Marcucci R et al (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919-933
9. Chan MY, Sun JL, Wang TY et al (2010) Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY. Am Heart J 160:1056-1064, 1064. e2
10. Montalescot G, Sideris G, Cohen R et al (2010) Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 103:213-223
11. Fernando H, Dart AM, Peter K et al (2011) Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. Thromb Haemost 105:933-944
12. O'Donoghue M, Antman EM, Braunwald E et al (2009) The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol 54:678-685
13. Wiviott SD, Trenk D, Frelinger AL et al (2007) Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116:2923-2932 (Pubitemid 350291199)
14. Bonello L, Pansieri M, Mancini J et al (2011) High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 58:467-473
15. Man M, Farmen M, Dumaual C et al (2010) Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol 50:929-940
16. Chan MY, Tan K, Tan H-C et al (2012) Functional significance and differential prevalence of CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. Pharmacogenomics 13:533-542